DPT vaccine

History

Diphtheria and tetanus toxoids and whole-cell Since the introduction of the combination vaccine, there has been an extensive decline in the incidence of pertussis, or whooping cough, the disease which the vaccine protects against. Additionally, the rates of disease have continued to decline as more extensive immunization strategies have been implemented, including booster doses and increased emphasis on increasing health literacy.

In the 20th century, the advancements in vaccinations helped to reduce the incidence of childhood pertussis and had a dramatically positive effect on the health of populations in the United States. However, in the early 21st century, reported instances of the disease increased 20-fold due to a downturn in the number of immunizations received and resulted in numerous fatalities. During the 21st century, many parents declined to vaccinate their children against pertussis for fear of perceived side effects, despite scientific evidence showing vaccines to be highly effective and safe. A study published in 2009 concluded the largest risk among unvaccinated children is not the contraction of side effects, but rather the disease that the vaccination aims to protect against.

DTP vaccines with acellular pertussis (DTaP; see below) were introduced in the 1990s. The reduced range of antigens causes fewer side effects, but results in a more expensive, shorter-lasting, and possibly less protective vaccine compared to DTwP.

Vaccination rates

In 2016, the US Centers for Disease Control and Prevention (CDC) reported that 80.4% of children in the US had received four or more DTaP vaccinations by 2 years of life. Vaccination rates for children aged 13–17 with one or more TDaP shots was 90.2% in 2019. Only 43.6% of adults (older than 18 years of age) have received a TDaP shot in the last 10 years. The CDC aimed to increase vaccination rate among 2-year-olds from 80.4% to 90.0%

The World Health Organization (WHO) estimated that 89% of people globally had received at least one dose of DTP vaccine and 84% had received three doses of the vaccine, completing the WHO-recommended primary series (DTP3). The WHO tracks DTP3 completion rates among one-year-olds on a yearly basis. The yearly DTP3 completion rate is considered a good proxy for the completeness of childhood vaccination in general, and numbers of children who have not received a first dose of DTP are used as a proxy for those who are not reached by vaccination programs at all (termed zero-dose children).

Combination vaccines with acellular pertussis

DTaP and Tdap are both combination vaccines against diphtheria, tetanus, and pertussis. The "a" indicates that the pertussis toxoids are acellular, while the lower-case "d" and "p" in "Tdap" indicate smaller concentrations of diphtheria toxoids and pertussis antigens.

DTaP

DTaP (also DTP and TDaP) is a combination vaccine against diphtheria, tetanus, and pertussis, in which the pertussis component is acellular. This is in contrast to whole-cell, inactivated DTP (or DTwP). The acellular vaccine uses selected antigens of the pertussis pathogen to induce immunity. Because it uses fewer antigens than the whole-cell vaccines, it is considered to cause fewer side effects, but it is also more expensive. Research suggests that the DTwP vaccine is more effective than DTaP in conferring immunity, because DTaP's narrower antigen base is less effective against current pathogen strains.

Tdap

Tdap (also TDP) is a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine. It was licensed in the United States for use in adults and adolescents in June 2005. Two Tdap vaccines are available in the US. In January 2011, the Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention (CDC) recommended the use of Tdap in adults of all ages, including those aged 65 years of age and older. In October 2011, in an effort to reduce the burden of pertussis in infants, the ACIP recommended that unvaccinated pregnant women receive a dose of Tdap. In October 2012, the ACIP voted to recommend the use of Tdap during every pregnancy. The ACIP and Canada's National Advisory Committee on Immunization (NACI) recommended that both adolescents and adults receive Tdap in place of their next Td booster (recommended to be given every ten years). Tdap and Td can be used as prophylaxis for tetanus in wound management. People who will be in contact with young infants are encouraged to get Tdap even if it has been less than five years since Td or TT to reduce the risk of infants being exposed to pertussis. NACI suggests intervals shorter than five years can be used for catch-up programs and other instances where programmatic concerns make five-year intervals difficult.

The World Health Organization recommends a pentavalent vaccine, combining the DTP vaccine with vaccines against Haemophilus influenzae type B and hepatitis B. Evidence on how effective this pentavalent vaccine is compared to the individual vaccines has not yet been determined.

A 2019 study found that state requirements mandating the use of the Tdap vaccine "increased Tdap vaccine take-up and reduced pertussis (whooping cough) incidence by about 32%."

Related combination vaccines

Excluding pertussis

DT and Td vaccines lack the pertussis component. The Td vaccine is administered to children over the age of seven as well as to adults. It is most commonly administered as a booster shot every 10 years. The Td booster shot may also be administered as protection from a severe burn or dirty wound. The DT vaccine is given to children under the age of seven who are unable to receive the pertussis antigen in the DTaP vaccine due to a contraindication.

Additional targets

Main article: DTaP-IPV vaccine, DTaP-IPV-HepB vaccine, Pentavalent vaccine, Hexavalent vaccine

In the United States, a combined inactivated polio (IPV), DTaP, and hepatitis B DTaP-IPV-HepB vaccine is available for children. In the UK, all babies born on or after 1 August 2017 are offered a hexavalent vaccine: DTaP, IPV, Haemophilus influenzae, and hepatitis B (DTaP-Hib-HepB-IPV in short).

As of 2023, most of the DTP vaccine procured by UNICEF is of the DTwP-HepB-Hib (pentavalent whole-cell) type. The UNICEF plans to procure the DTwP-HepB-Hib-IPV (hexavalent whole-cell) vaccine starting in 2024.

Contraindications

The DPT vaccine should be avoided in persons who experienced a severe allergic reaction, such as anaphylaxis, to a past vaccine containing tetanus, diphtheria, or pertussis. It should also be avoided in persons with a known severe allergy to an ingredient in the vaccine. If the reaction was caused by tetanus toxoids, the CDC recommends considering a passive immunization with tetanus immune globulin (TIG) if a person has a large or unclean wound. The DPT vaccine should also be avoided if a person developed encephalopathy (seizures, coma, declined consciousness) within seven days of receiving any pertussis-containing vaccine and the encephalopathy cannot be traced to another cause. A DT vaccine is available for children under the ages of seven who have contraindications or precautions to pertussis-containing vaccines.

Side effects

DTaP

Common side effects include soreness where the shot was given, fever, irritability, tenderness, loss of appetite, and vomiting. Most side effects are mild to moderate and may last from one to three days. More serious but rare reactions after a DTaP vaccination may include seizures, lowered consciousness, or a high fever over 105 F. Allergic reactions are uncommon, but are medical emergencies. Signs of an allergic reaction include hives, dyspnea, wheezing, swelling of face and throat, syncope, and tachycardia and the child should be rushed to the nearest hospital.

Tdap

Common side effects include pain or swelling where the shot was given, mild fever, headache, tiredness, nausea, vomiting, diarrhea, and stomach ache. Allergic reactions are possible and have the same presentation and indications as described above for allergic reactions in DTaP. Any individual who has experienced a life-threatening allergic reaction after receiving a previous dose of diphtheria, tetanus, or pertussis containing vaccine should not receive the Tdap vaccination.

In pregnant women, research suggests that Tdap administration may be associated with an increased risk of chorioamnionitis, a placental infection. Increased incidence of fever is also noted in pregnant women. Despite the observed increase in incidence of chorioamnionitis in pregnant women following Tdap administration, there has been no observed increase in the incidence of preterm birth, for which chorioamnionitis is a risk factor. Research has not discerned an association between Tdap administration during pregnancy and other serious pregnancy complications such as neonatal death and stillbirth. An association between Tdap administration during pregnancy and pregnancy-related hypertensive disorders (such as pre-eclampsia) has not been identified.

Immunization schedules and requirements

Australia

In Australia, the DTP vaccine is part of the National Immunisation Program (NIP). The vaccine is administered to infants in a series of doses: the first three doses are given at 2, 4, and 6 months of age, followed by a fourth dose at 18 months and a fifth dose at 4 years. Adolescents receive a single booster dose at 12–13 years.

Adults are recommended to receive a dTpa booster every 10 years, especially those in close contact with infants. Pregnant women are advised to receive a dTpa booster during each pregnancy, ideally between 20 and 32 weeks of gestation, to protect newborns from pertussis.

France

In France, children are given DTaP-Hib-HepB-IPV vaccines at 2 months (first dose) and 4 months (second dose) with a booster at 11 months of age. A tetravalent booster for diphtheria, pertussis, tetanus and poliomyelitis is given at 6 years, at 11–13 years, then at 25, 45, 65 years of age, then every 10 years.

Netherlands

In the Netherlands, pertussis is known as kinkhoest and DKTP refers to the DTaP-IPV combination vaccine against diphtheria, kinkhoest, tetanus, and polio. DTaP is given as part of the National Immunization Program.

United Kingdom

In the United Kingdom, Td/IPV is called the "3-in-1 teenage booster" and protects against tetanus, diphtheria and polio. It is given by the NHS to all teenagers aged 14 (the hexavalent vaccine is given to infants and provides the first stage of protection against diphtheria, tetanus, and polio, as well as pertussis, Haemophilus influenzae type B and hepatitis B). Subsequent boosters are recommended for foreign travellers where more than 10 years has passed since their last booster. This is provided on the NHS free of charge due to the significant risk that an imported case of polio could pose to public health in Britain.

United States

The standard immunization regimen for children within the United States is five doses of DTaP between the ages of two months and fifteen years. To be considered fully vaccinated, the Centers for Disease Control and Prevention (CDC) typically requires five doses of Tdap. The CDC recommends that children receive their first dose at two months, the second dose at four months, the third dose at six months, the fourth dose between 15 and 18 months, and the fifth dose between 4–6 years. If the fourth dose of the DTaP immunization regimen falls on or subsequent to the recipient's fourth birthday, the CDC states that only four doses are required to be fully vaccinated. In the instance that an individual under 18 has not received the DTaP vaccine, individuals should be vaccinated on the schedule in accordance with the vaccination "catch up schedule" provided by the CDC.

Infants younger than twelve months of age, specifically less than three months of age, are at highest risk of acquiring pertussis. In U.S., there is no current tetanus-diphtheria-pertussis vaccination (whooping cough) recommended or licensed for new born infants. As a result, in their first few months of life, unprotected infants are at highest risk of life-threatening complications and infections from pertussis. Infants should not receive pertussis vaccination younger than six weeks of age. Ideally, Infants should receive DTaP (name of whooping cough vaccine for children from age 2 months through 6 years) at 2, 4, 6 months of age and they are not protected until the full series is completed. To protect infants younger than twelve months of age not vaccinated with Tdap against pertussis, ACIP also recommends adults (e.g., parents, siblings, grandparents, childcare providers, and healthcare personnel) and children to receive Tdap at least two weeks before being in contact with the infant.

The CDC recommends that adults who have received their childhood DTP series receive a Td or Tdap booster every ten years. For adults that have not received the DTP series, the CDC recommends a three-part vaccine series followed by a Td or Tdap booster every ten years.

In pregnancy

According to guidelines of the Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention (CDC), one dose of Tdap is recommended during each pregnancy to ensure protection against pertussis in newborn infants. Optimal timing to administer a dose of Tdap during each pregnancy is between 27 through 36 weeks gestation. If Tdap is administered early in pregnancy, it is not recommended to administer again during the 27 through 36 weeks gestation period as only one dose is recommended during pregnancy. In October 2022, Boostrix (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed [Tdap]) was approved for immunization during the third trimester of pregnancy to prevent pertussis, commonly known as whooping cough, in infants younger than two months of age.

Pregnant women who have not previously vaccinated with Tdap (i.e., have never received DTP, DTaP, or DT as child or Td or TT as an adult) are recommended to receive a series of three Td vaccinations starting during pregnancy to ensure protection against maternal and neonatal tetanus. In such cases, administration of Tdap is recommended after 20 weeks' gestation, and in earlier pregnancy a single dose of Tdap can be substituted for one dose of Td, and then the series completed with Td. For pregnant women not previously vaccinated with Tdap, if Tdap is not administered during pregnancy, it should be administered immediately postpartum. Postpartum administration of TDaP is not equivalent to administration of the vaccination during pregnancy. Because the vaccine is administered postpartum, the mother is unable to develop antibodies that can be transferred to the infant in utero, consequently, leaving the infant vulnerable to the diseases preventable by the Tdap Vaccine. Postpartum administration of the TdaP vaccine to the mother seeks to reduce the likelihood that the mother will contract disease that can be subsequently passed on the infant, albeit there will still be a two-week period prior to the protective effects of the vaccine setting in. Postpartum administration is an extension of the concept of "cocooning", a term that refers to the full vaccination of all individuals that may come into direct contact with the infant. Cocooning, like postpartum Tdap administration, is not recommended by the CDC. Cocooning depends on ensuring full vaccination of all individuals that the infant may come into contact with, and there may be financial, administrative or personal barriers that preclude full and timely vaccination of all individuals within the "cocoon".

Brand names

Australia

United States

, there are seven DTaP vaccines and two Tdap vaccines licensed and available for use in the United States. All of them are indicated as childhood vaccinations with the schedules as follows:

References

References

1. "Global vaccination coverage: Diphtheria-tetanus-pertussis (DTP3) immunization".
2. (29 May 2007). "Boostrix Product information".
3. (22 October 2010). "Boostrix Product information".
4. (27 July 2006). "Adacel Product information".
5. (26 May 2022). "Boostrix-IPV 0.5 mL injection syringe (96137)".
6. (13 March 2025). "Boostrix-IPV (GlaxoSmithKline Australia Pty Ltd)".
7. (26 May 2022). "Boostrix 0.5 mL injection pre-filled syringe (158363)".
8. "standing orders for Administering Diphtheria, Tetanus, and Acellular Pertussis (DTaP)Vaccine to Children YoungerThan Age 7Years".
9. "standing orders for Administering Tdap/Td Vaccine to Children and Teens Age 7 Years and Older".
10. "standing orders for Administering Td/Tdap Vaccine to Adults".
11. "standing orders for Administering Tdap During Pregnancy".
12. "List of nationally authorised medicinal products".
13. (1 April 2020). "DTaP (Diphtheria, Tetanus, Pertussis) Vaccine Information Statement".
14. (26 April 2021). "Vaccine Types".
15. (April 2018). "Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP)". MMWR. Recommendations and Reports.
16. "Understanding Six Types of Vaccine Technologies".
17. (2020). "Birth-18 Years Immunization Schedule".
18. (17 May 2013). "Vaccine Timeline: Historic Dates and Events Related to Vaccines and Immunization". Immunization Action Coalition.
19. (2016). "Pulmonary Dysfunction and Disease".
20. (May 2012). "Lessons learned and applied: what the 20th century vaccine experience can teach us about vaccines in the 21st century". Human Vaccines & Immunotherapeutics.
21. (26 May 2009). "Is Vaccine Refusal Worth The Risk?". [[NPR]].
22. (June 2023). "Diphtheria Tetanus and Pertussis Containing Vaccines: Market and Supply Update".
23. (6 September 2022). "FastStats". U.S. [[Centers for Disease Control and Prevention]] (CDC).
24. "Increase the coverage level of 4 doses of the DTaP vaccine in children by age 2 years — IID‑06".
25. "Diphtheria tetanus toxoid and pertussis (DTP) vaccination coverage".
26. (2021). "Prevalence, Trends and Conditions for the DTP3 Vaccine: A 25-Year Historical Perspective". Risk Management and Healthcare Policy.
27. "IA2030 IG 2.1: Number of zero dose children". World Health Organization.
28. (January 2011). "The difference between Tdap and DTaP; dabigatran versus warfarin". JAAPA.
29. (15 June 2020). "Safety Information for Diphtheria, Tetanus, and Pertussis Vaccines".
30. (February 2017). "Choosing from Whole Cell and Acellular Pertussis Vaccines-Dilemma for the Developing Countries". Iranian Journal of Public Health.
31. (2019). "Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines". Frontiers in Immunology.
32. (2020). "Diphtheria, Tetanus, and Whooping Cough Vaccination". U.S. [[Centers for Disease Control and Prevention]] (CDC).
33. (January 2011). "Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010". MMWR. Morbidity and Mortality Weekly Report.
34. (February 2013). "Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012". MMWR. Morbidity and Mortality Weekly Report.
35. (January 2020). "Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2019". MMWR. Morbidity and Mortality Weekly Report.
36. (March 2006). "Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP)". MMWR. Recommendations and Reports.
37. "ACIP Votes to Recommend Use of Combined Tetanus, Diphtheria and Pertussis (Tdap) Vaccine for Adults".
38. (14 October 2005). "Interval Between Administration of Vaccines Against Diphtheria, Tetanus, and Pertussis".
39. (December 2006). "Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel". MMWR. Recommendations and Reports.
40. (2020). "General Recommendations on Immunization". U.S. [[Centers for Disease Control and Prevention]] (CDC).
41. (April 2012). "Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB)". The Cochrane Database of Systematic Reviews.
42. (2019). "Direct and Spillover Effects of Middle School Vaccination Requirements". American Economic Journal: Economic Policy.
43. (1 March 2020). "Td (Tetanus, Diphtheria) Vaccine Information Statement".
44. (13 June 2016). "Tetanus and Diphtheria (Td) Vaccine".
45. "Diphtheria Vaccination".
46. "UpToDate".
47. (2008). "Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book)". Public Health Foundation.
48. (6 November 2019). "Pediarix". U.S. [[Food and Drug Administration]] (FDA).
49. "Hexavalent 6-in-1 vaccine to be made available to newborn babies".
50. (2015). "Epidemiology and Prevention of Vaccine-Preventable Diseases". U.S. [[Centers for Disease Control and Prevention]] (CDC).
51. (2015). "Epidemiology and Prevention of Vaccine-Preventable Diseases". U.S. [[Centers for Disease Control and Prevention]] (CDC).
52. "UpToDate".
53. (27 June 2022). "Diphtheria-Tetanus-Pertussis Vaccine Information Statement". U.S. [[Centers for Disease Control and Prevention]] (CDC).
54. (February 2020). "Safety and effectiveness of acellular pertussis vaccination during pregnancy: a systematic review". BMC Infectious Diseases.
55. (November 2017). "Efficacy and safety of pertussis vaccination for pregnant women — a systematic review of randomised controlled trials and observational studies". BMC Pregnancy and Childbirth.
56. "National Immunisation Program Schedule". Australian Government Department of Health.
57. "Les vaccins à tous les âges—Calendrier 2024".
58. (28 April 2025). "Le calendrier des vaccinations".
59. "Dutch National Immunization Program".
60. (31 July 2019). "3-in-1 teenage booster overview".
61. (18 October 2017). "Tetanus".
62. (23 October 2017). "Travel vaccinations".
63. (6 May 2022). "Summary of Pertussis Vaccination Recommendations". U.S. [[Centers for Disease Control and Prevention]] (CDC).
64. (14 February 2019). "Pertussis". U.S. [[Centers for Disease Control and Prevention]] (CDC).
65. (February 2014). "Protecting infants from pertussis". Canadian Family Physician.
66. (3 February 2020). "Tetanus, diphtheria, and pertussis vaccination".
67. (April 2018). "Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA". Vaccine.
68. (10 April 2019). "Tdap (Pertussis) Vaccine and Pregnancy".
69. (7 October 2022). "FDA Approves Vaccine for Use During Third Trimester of Pregnancy to Prevent Whooping Cough in Infants Younger Than Two Months of Age".
70. [http://www.icsi.org/prenatal_care_4/prenatal_care__routine__full_version__2.html Health Care Guideline: Routine Prenatal Care. Fourteenth Edition.] {{webarchive. link. (24 June 2012 By the Institute for Clinical Systems Improvement. July 2010.)
71. (October 2011). "Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months --- Advisory Committee on Immunization Practices (ACIP), 2011". MMWR. Morbidity and Mortality Weekly Report.
72. (15 January 2021). "Tdap (Pertussis) Vaccine and Pregnancy". U.S. [[Centers for Disease Control and Prevention]] (CDC).
73. (4 June 2018). "Adacel".
74. (18 July 2020). "Adacel (Pertussis Vaccine-Acellular Combined with Diphtheria and Tetanus Toxoids (Adsorbed))".
75. "Triple Antigen IPV".
76. (5 June 2018). "Adacel Polio".
77. (18 July 2020). "Adacel Polio (Pertussis Vaccine — Acellular and Diphtheria and Tetanus Toxoids (Adsorbed) Combined with Inactivated Poliovirus Type 1, 2 and 3 (Vero cell))".
78. (22 January 2020). "About Diphtheria, Tetanus, and Pertussis Vaccination".
79. (7 July 2020). "Licensed Biological Products with Supporting Documents".
80. (14 May 2020). "Daptacel (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated), clostridium tetani toxoid antigen (formaldehyde inactivated), bordetella pertussis toxoid antigen (glutaraldehyde inactivated), bordetella pertussis filamentous hemagglutinin antigen- formaldehyde inactivated, bordetella pertussis pertactin antigen, and bordetella pertussis fimbriae 2/3 antigen injection, suspension)". Sanofi Pasteur Inc..
81. (22 July 2017). "Daptacel".
82. (6 November 2019). "Infanrix- diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed suspension". GlaxoSmithKline Biologicals SA.
83. (22 July 2017). "Infanrix".
84. (6 November 2019). "Kinrix- diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine injection, suspension". GlaxoSmithKline Biologicals SA.
85. (22 July 2017). "Kinrix".
86. (6 November 2019). "Pediarix (diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis b- recombinant and inactivated poliovirus vaccine combined injection, suspension". GlaxoSmithKline Biologicals SA.
87. (23 July 2017). "Pediarix".
88. (5 June 2020). "Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate- tetanus toxoid conjugate vaccine kit)". Sanofi Pasteur Inc..
89. (22 July 2017). "Pentacel".
90. (20 April 2020). "Quadracel- diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine injection, suspension". Sanofi Pasteur Inc..
91. (22 July 2017). "Quadracel".
92. (17 July 2025). "Vaxelis- diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, haemophilus b conjugate and hepatitis b vaccine injection, suspension".
93. (12 April 2023). "Vaxelis".
94. (26 March 2020). "Adacel Tdap (clostridium tetani toxoid antigen (formaldehyde inactivated), corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated), bordetella pertussis toxoid antigen (glutaraldehyde inactivated), bordetella pertussis filamentous hemagglutinin antigen- formaldehyde inactivated, bordetella pertussis pertactin antigen, and bordetella pertussis fimbriae 2/3 antigen injection, suspension)".
95. "Adacel".
96. (25 April 2019). "Boostrix- tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed suspension".
97. "Boostrix".